Azenta Shares Crater Following Q1 Earnings Miss and Widening Loss

Shares of the life sciences specialist dropped 22% to $28.70 during morning trading, marking a significant blow to a stock that has already shed 45% of its value over the past year. The sell-off followed a financial report showing a net loss of $15.4 million, or 34 cents per share, compared to an $11 million loss during the same period last year.

Revenue Realities and Organic Decline

On an adjusted basis, Azenta delivered earnings of 9 cents per share, missing the 14 cents per share anticipated by analysts, according to FactSet data. While the company managed to grow its top-line revenue to $148.6 million—narrowly beating the $147.1 million consensus—the underlying performance suggested a cooling market. When adjusted for foreign exchange fluctuations, organic revenue actually declined by 1% year-over-year.

The widening loss highlights the ongoing pressure on life sciences providers as they navigate shifting demand and currency headwinds. While Azenta’s revenue remains resilient on paper, the failure to translate that volume into bottom-line profitability remains a primary hurdle for the company as it attempts to stabilize its market position.